Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002107 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
A Phase 1 study, sponsored by Chiron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002107: Completed Phase 1 study, sponsored by Chiron Corporation.
NCT00002107 is a Phase 1 study that has completed, run by Chiron Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002107, a Phase 1 study, has completed, sponsored by Chiron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene glycolated IL-2 and high-dose continuous infusion IL-2 studies. To evaluate the incidence and level of anti-IL-2 antibody formation to subcutaneously administered Proleukin in this patient population.
Interventions
- DRUG Aldesleukin
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002107 record still lists
NCT00002107 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Aldesleukin is the first listed.
NCT00002107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002107 about?
NCT00002107 is a clinical study titled "A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients". To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients. To identify a tolerable subcutaneous regimen that will replicate the immunologic improvement demonstrated in the outpatient polyethylene g...
What is the current status of trial NCT00002107?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002107?
The interventions under investigation include: Aldesleukin (DRUG).
Who is sponsoring clinical trial NCT00002107?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.